Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 233 ()
DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study

ECCO'20 Vienna

Year: 2020
Authors:

M. Høivik1, M. Lördal2, J. Burisch3, E. Langholz4, T. Knudsen5, M. Voutilainen6, B. Moum1, K. Anisdahl1, B. Saebo7, P. Haiko8, C. Malmgren9, M. Coskun10, H.O. Melberg11

1Department of Gastroenterology, Oslo University Hospital, Oslo, Norway, 2Department of Gastroenterology and Hepatology, Danderyds Hospital, Stockholm, Sweden, 3Department of Gastrounit- Medical Division, Hvidovre University Hospital, Hvidovre, Denmark, 4Department of Medical Gastroenterology, Herlev Hospital, Herlev, Denmark, 5Department of Medicine, Hospital South West Denmark, Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, 6Department of Gastroenterology, University of Turku, Turku, Finland, 7Takeda AS, Medical Affairs, Asker, Norway, 8Takeda Oy, Medical Affairs, Helsinki, Finland, 9Department of Medical Affairs, Takeda Pharma AB, Stockholm, Sweden, 10Department of Medical Affairs, Taastrup, Denmark, 11Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway

DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)

ECCO'20 Vienna

Year: 2020
Authors:

M. Barreiro-de Acosta1, A. Gutierrez2, Y. Zabana3, B. Beltran4, X. Calvet5, M. Chaparro6, E. Domènech7, M. Esteve3, J. Panés8, J.P. Gisbert6, P. Nos4, on behalf of GETECCU

1Department of Gastroenterology- IBD Unit, University Hospital Santiago De Compostela CHUS, Santiago De Compostela, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gatroenterology, Hospital Universitario de Alicante, Alicante, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Hospital Universitari Mútua Terrassa, Terrasa, Spain, 4Centro de de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD-, Gastroenterology, Hospital Universitario La Fe, Valencia, Spain, 5Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Corporació Sanitaria Universitària Parc Taulí, Sabadell, Spain, 6Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa IIS-IP, Madrid, Spain, 7Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Germans Trias i Pujol, Badalona, Spain, 8Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Hospital Clinic, Gastroenterology, Barcelona, Spain

DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe

ECCO'20 Vienna

Year: 2020
Authors:

Z. Guo, Y. Zhu, L. Cao, Y. Li, Z. Wang, W. Zhu

Department of General Surgery, Jinling Hospital, Nanjing, China

DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial

ECCO'20 Vienna

Year: 2020
Authors:

E.V. Loftus Jr1, S.W. Schreiber2, S. Danese3, L. Peyrin-Biroulet4, J.F. Colombel5, B.E. Sands5, S. Wang6, J. Chen7, R.A. Lirio8

1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, USA, 2Department of Medicine, University Hospital Schleswig-Holstein, Kiel, Germany, 3Department of Gastrointestinal Immunopathology, Humanitas University, Milan, Italy, 4Department of Gastroenterology, Nancy University Hospital, Nancy, France, 5Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 6Global Outcomes Research and Epidemiology, Takeda, Cambridge, USA, 7Statistics and Quantitative Sciences, Takeda, Cambridge, USA, 8Clinical Science, Takeda, Cambridge, USA

DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort

ECCO'20 Vienna

Year: 2020
Authors:

E. Barnes1, J. Hanson2, M. Regueiro3, S. Saha4, B.E. Sands5, D. Rubin6, M. Dubinsky7, C. Siegel8, D. Gazis9, J. Crawford10, M. Long1

1Department of Gastroenterology, University of North Carolina, Chapel Hill, USA, 2Department of Gastroenterology, Atrium Health, Charlotte, USA, 3Department of Gastroenterology, Cleveland Clinic, Cleveland, USA, 4Department of Gastroenterology, University of Wisconsin, Madison, USA, 5Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Medical Center, New York, USA, 6Department of Gastroenterology, University of Chicago, Chicago, USA, 7Department of Pediatric Gastroenterology and Nutrition, Mount Sinai School of Medicine, New York, USA, 8Department of Gastroenterology, Dartmouth Hitchcock, Lebanon, USA, 9Department of Statistics, TARGET PharmaSolutions, Durham, USA, 10Scientific and Medical Affairs, TARGET PharmaSolutions, Durham, USA

DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

C.G. af Björkesten1, T. Ilus2, T. Hallinen3, E. Soini3, A. Eberl1, K. Hakala4, M. Heikura5, E. Hirsi6, A. Jussila2, M. Kellokumpu7, R. Koskela8, I. Koskinen9, V. Moilanen10, C. Nielsen11, U. Nieminen1, H. Nuutinen12, M. Heikkinen13, U.M. Suhonen14, J. Tillonen15, K. Utriainen16, I. Vihriälä17, C. Wennerström18,19, A. Borsi20, R. Nissinen21, M. Koivunen21, T. Sipponen1

1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Tampere University Hospital, Tampere, Finland, 3ESiOR Oy, Kuopio, Finland, 4Kanta-Häme Central Hospital, Hämeenlinna, Finland, 5North Karelia Central Hospital, Joensuu, Finland, 6South Karelia Central Hospital, Lappeenranta, Finland, 7Lapland Central Hospital, Rovaniemi, Finland, 8Oulu University Hospital, Oulu, Finland, 9Central Finland Central Hospital, Jyväskylä, Finland, 10Satakunta Central Hospital, Pori, Finland, 11Vaasa Central Hospital, Vaasa, Finland, 12Turku University Hospital, Turku, Finland, 13Kuopio University Hospital, Kuopio, Finland, 14Kainuu Central Hospital, Kajaani, Finland, 15Päijät-Häme Central Hospital, Lahti, Finland, 16Turku University Hospital Salo Hospital, Salo, Finland, 17Central Ostrobothnia Central Hospital, Kokkola, Finland, 18Janssen Cilag, Medical Affairs, Solna, Sweden, 19Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, 20Janssen Cilag Limited, Emea Hemar, High Wycombe, UK, 21Medical Affairs, Janssen Cilag Oy, Espoo, Finland

DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure

ECCO'20 Vienna

Year: 2020
Authors:

E. Van Praag BSc1, R. Hompes1, C. Buskens1, P. Tanis1, M. Duijvestein2, W. Bemelman1

1Department of Surgery, Amsterdam UMC-location AMC, Amsterdam, The Netherlands, 2Department of Gastroenterology and Hepatology, Amsterdam UMC-location AMC, Amsterdam, The Netherlands

DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort

ECCO'20 Vienna

Year: 2020
Authors:

S. Lin1,2, N. Chanchlani1,2, B.M. Invergo3, M.W. Anderson3, H.M. Guay4, M. Reppell4, J.W. Butler4, J.R. Goodhand1,2, T. Ahmad1,2, N.A. Kennedy1,2, Exeter IBD Pharmacogenetics Research Group

1Exeter IBD Pharmacogenetics Research Group, University of Exeter, Exeter, UK, 2Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK, 3Translational Exchange @ Exeter- Living Systems Institute, University of Exeter, Exeter, UK, 4Department of Research and Development, AbbVie Inc., North Chicago, USA

DOP29 Elevation of a novel blood-based gene signature in a severe Crohn’s disease (CD) subtype preceding surgery defines and predicts a post-surgical decrease in pro-inflammatory pathway activation

ECCO'20 Vienna

Year: 2020
Authors:

R. Gonsky1, P. Fleshner2, G. Botwin1, E. Biener-Ramanujan1, D. McGovern1, S. Targan1

1Cedars Sinai Medical Center, Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California, USA, 2Cedars Sinai Medical Center, Department of Surgery, Los Angeles, CA, USA

DOP30 Multi-‘omics profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse

ECCO'20 Vienna

Year: 2020
Authors:

N. Borren1, D. Plichta2, A. joshi1, G. Bonilla3, R. Sadreyev3, H. Vlamakis2, R. Xavier1, A. Ananthakrishnan1

1Massachusetts General Hospital, Division of Gastroenterology, Boston, USA, 2Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, USA, 3Department of Molecular Biology, Massachusetts General Hospital, Boston, USA

DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches

ECCO'20 Vienna

Year: 2020
Authors:

S. Verstockt1,2, N. Verplaetse2,3, D. Raimondi3, B. Verstockt1,4, E. Glorieus5, M. De Decker6, L. Hannes2, V. Ballet4, E. Vandeput1, Y. Moreau3, M. Ferrante1,4, D. Laukens5, F. Mana6, M. De Vos5, S. Vermeire1,4, I. Cleynen2

1Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 2Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, 3Department of Electrical Engineering ESAT, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 5Department of Gastroenterology, University Hospital of Ghent, Ghent, Belgium, 6Department of Gastroenterology, University Hospitals Brussels, Brussels, Belgium

DOP32 Clinical and molecular characterisation of patients with durable response to ustekinumab induction therapy: Results from the UNIFI phase 3 studies in moderate-to-severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J.R. Friednman

Janssen Research and Development- LLC, Immunology, Spring House, USA

DOP33 Stratification of patients for treatment with adalimumab by a combination of immune-profiling and in vivo efficacy studies in a novel mouse model of ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

R. Gropp1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, S. Sterz2, L. Holdt2, F. Beigel3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1

1Hospital of the Ludwig Maximilian Universität, General, Visceral- und Transplantation Surgery, München, Germany, 2Hospital of the Ludwig Maximilian Universität, Institute of Laboratory Medicine, München, Germany, 3Hospital of the Ludwig Maximilian Universität, Department of Medicine II, München, Germany

DOP34 Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulas

ECCO'20 Vienna

Year: 2020
Authors:

R.S. Bruckner1, E. Nissim-Eliraz2, N. Marsiano2, E. Nir2, H. Shemesh2, M. Leutenegger1, C. Gottier1, S. Lang1, M.R. Spalinger1, S. Leibl3, G. Rogler1,4, S. Yagel5, M. Scharl1,4, N.Y. Shpigel2

1Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 2Department of Basic Sciences, Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel, 3Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland, 4Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland, 5Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel

DOP35 Monitoring of mucosal T cells subsets under biotherapies in IBD: responders exhibit a phenotype similar to healthy controls

ECCO'20 Vienna

Year: 2020
Authors:

N. Hammoudi1, K. Perez1, D. Hassid1, M.L. Tran Minh1, J.M. Gornet1, C. Baudry1, N. Lourenco1, B. Gergaud2, V. Chardiny2, J. Bonnet1, L. Le Bourhis2, M. Allez1

1APHP Saint Louis, Gastroenterology, Paris, France, 2INSERM, Unité U1160, Paris, France

DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

G.Y. SHIN1, Y.M. Park1, E. Ha2, K.N. Gu2, K. Kim2, C.K. Lee1, H.J. Kim1

1Department of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University College of Medicine, Seoul, Korea Republic of, 2Department of Biology, Kyung Hee University College of Sciences, Seoul, Korea Republic of

DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study

ECCO'20 Vienna

Year: 2020
Authors:

A. Cremer1, P. Demetter2, M. De Vos3, J.F. Rahier4, F. Baert5, T. Moreels6, E. Macken6, E. Louis7, S. Vermeire8, D. Franchimont1, Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group

1Department of Gastroenterology, Erasme University Hospital- ULB, Brussels, Belgium, 2Institut Jules Bordet, Department of Pathology, Brussels, Belgium, 3Department of Gastroenterology, University Hospital Ghent, Ghent, Belgium, 4Department of Gastroenterology, CHU UCL Namur, Yvoir, Belgium, 5Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 6Department of Gastroenterology, University Hospital Antwerp, Edegem, Belgium, 7Department of Gastroenterology, University Hospital Liège, Liège, Belgium, 8Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium

DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics

ECCO'20 Vienna

Year: 2020
Authors:

C. Liefferinckx1,2, M. El hamdi1, M. Fassin2, A. Cremer1,2, C. Minsart1,2, L. Amininejad1, V. Wambacq1, A. Van Gossum1, D. Franchimont1,2

1Department of Gastroenterology, Hopital Erasme, Brussels, Belgium, 2Laboratory of Experimental Gastroenterology, ULB, Brussels, Belgium

DOP39 The first prospective, multicentre, randomised controlled trial on discontinuation of infliximab in ulcerative colitis in remission; endoscopic normalisation does not guarantee successful withdrawal

ECCO'20 Vienna

Year: 2020
Authors:

T. Kobayashi1, S. Motoya2, S. Nakamura3, T. Yamamoto4, M. Nagahori5, S. Tanaka6, T. Hisamatsu7, F. Hirai8, H. Nakase9, K. Watanabe10, T. Matsumoto11, M. Tanaka12, T. Abe13, Y. Suzuki14, M. Watanabe5, T. Hibi1, HAYABUSA

1Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan, 2IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 3Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Nishinomiya, Japan, 4Yokkaichi Hazu Medical Centre, IBD Centre, Yokkaichi, Japan, 5Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan, 6Department of Endoscopy and Medicine, Hiroshima University, Hiroshima, Japan, 7Department of Gastroenterology and Hepatology, School of Medicine, Kyorin University, Mitaka, Japan, 8Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 9Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan, 10Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan, 11Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan, 12Department of Pathology, Hirosaki Municipal Hospital, Morioka, Japan, 13Department of Data Science, Yokohama City University, Yokohama, Japan, 14IBD Center, Toho University Sakura Medical Center, Sakura, Japan

DOP40 Does levels of concerns and expectations predict IBD disease status?

ECCO'20 Vienna

Year: 2020
Authors:

V. Pittet, Swiss IBD Cohort Study

Center for Primary Care and Public Health, University of Lausanne, Epidemiology and Health Services, Lausanne, Switzerland

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 233 ()